Optic tract astrocytoma

Summary

Optic tract astrocytoma (MONDO:0024649) is a disease. A subtype of sensory system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	optic tract astrocytoma
Mondo ID	MONDO:0024649
NCIT	C7533
UMLS	C1336971
MedGen	237052
GARD	0025445
Anatomy (UBERON)	UBERON:0001908
Is cancer (heuristic)	no

Also known as: astrocytoma (excluding glioblastoma) of optic tract · optic tract astrocytoma · optic tract astrocytoma (excluding glioblastoma) · visual pathway astrocytoma

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › optic tract astrocytoma

Related subtypes (6): nasal cavity cancer, ocular cancer, malignant ear neoplasm, auditory system cancer, tongue cancer, paranasal sinus cancer

Subtypes (2): optic nerve astrocytoma, childhood optic tract astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.